Obinutuzumab and Chemotherapy for Front-Line Treatment of Follicular Lymphoma Grade 3B and Composite Follicular Lymphoma: A Study of the Croatian Cooperative Group for Hematologic Diseases (KroHem)

Background

Data on outcomes of follicular lymphoma grade 3B (FL gr.3B) and composite lymphoma (FL/large B-cell lymphoma (B-LCL)) are scarce and the effect of obinutuzumab is unknown. Patients and methods: We analyzed outcomes of patients with FL gr.3B & FL/B-LCL receiving front-line treatment with obinutuzumab-chemotherapy combinations and compared them to previously published cohorts with FL gr.1–3A and diffuse large B-cell lymphoma (DLBCL).